Vaccine adjuvants to engage the cross-presentation pathway.
Vaccine adjuvants to engage the cross-presentation pathway.
复制标题
疫苗佐剂可以接合交叉呈递途径。
DOI：
10.3389/fimmu.2022.940047
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
佐剂是疫苗不可缺少的组成部分，用于刺激对非复制、灭活和亚单位抗原的最佳免疫反应。激发平衡的体液和T细胞介导的免疫对于防御由复杂的细胞内病原体引起的疾病（如结核病、疟疾和艾滋病）至关重要。然而，目前使用的疫苗引起强烈的抗体反应，但很少刺激CD8细胞毒性T淋巴细胞（CTL）反应。为了诱发有效的CTL记忆，疫苗需要参与交叉呈递途径，这一要求一直是开发产生有效T细胞免疫的亚单位疫苗的关键瓶颈。在这篇综述中，我们关注于DC交叉呈递的最新见解，以及临床相关的疫苗佐剂，如铝基纳米颗粒、油包水乳剂（MF59）佐剂、皂苷基佐剂和toll样受体（TLR）配体，在多大程度上调节DC交叉呈递效率。此外，我们讨论了使用基于卡波默的佐剂作为下一代佐剂平台以引发平衡的抗体和t细胞免疫的可行性。了解DC交叉呈递的分子机制和佐剂的作用方式将为合理设计需要平衡抗体和T细胞免疫的传染病和癌症疫苗铺平道路。
Adjuvants are indispensable components of vaccines for stimulating optimal immune responses to non-replicating, inactivated and subunit antigens. Eliciting balanced humoral and T cell-mediated immunity is paramount to defend against diseases caused by complex intracellular pathogens, such as tuberculosis, malaria, and AIDS. However, currently used vaccines elicit strong antibody responses, but poorly stimulate CD8 cytotoxic T lymphocyte (CTL) responses. To elicit potent CTL memory, vaccines need to engage the cross-presentation pathway, and this requirement has been a crucial bottleneck in the development of subunit vaccines that engender effective T cell immunity. In this review, we focus on recent insights into DC cross-presentation and the extent to which clinically relevant vaccine adjuvants, such as aluminum-based nanoparticles, water-in oil emulsion (MF59) adjuvants, saponin-based adjuvants, and Toll-like receptor (TLR) ligands modulate DC cross-presentation efficiency. Further, we discuss the feasibility of using carbomer-based adjuvants as next generation of adjuvant platforms to elicit balanced antibody- and T-cell based immunity. Understanding of the molecular mechanism of DC cross-presentation and the mode of action of adjuvants will pave the way for rational design of vaccines for infectious diseases and cancer that require balanced antibody- and T cell-based immunity.
DOI：
10.1007/s00262-021-02984-7
发表时间：
2022-03
期刊：
Cancer immunology, immunotherapy : CII
影响因子：
--
作者：
Marijt KA;Griffioen L;Blijleven L;van der Burg SH;van Hall T
通讯作者：
van Hall T